



12

Bibliografía

1.- North., A.B., South, C.D. Cancer Incidence in Antarctica (1998-2002). In: Curado. M. P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M. and Boyle. P., eds (2007).Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160, Lyon, IARC.

2.- Cervical Cancer Incidence and Mortality Worldwide in 2008. Disponible en: <http://globocan.iarc.fr/factsheets/cancers/cervix.asp> (Acceso 17 de Julio 2010)

3.- La situación del cáncer en España. Área de epidemiología ambiental y cáncer. Centro Nacional de Epidemiología Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Centro de publicaciones. Madrid. 2005. Disponible en: <http://cne.isciii.es/mortal/>. (Acceso 13 de Octubre de 2009)

4.- Walboomers JM; Jacobs MV; Manos MM; Bosch FX; Kummer JA; Shah KV; Snijders PJ; Peto J; Meijer CJ; Munoz N. Human papillomavi-

rus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;189(1):12-9.

5.- De Sanjosé S, Díaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. *Lancet Infect Dis.* 2007;7(7):453-9

6.- Schiffman M; Castle PE; Jerónimo J; Rodríguez AC; Wacholder S. Human papillomavirus and cervical cancer. *Lancet.* 2007 8; 370: 890-907.

7.- Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr, Zaza S; GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ.* 2004 19; 328(7454):1490.

- 8.- Marzo M, Alonso P. Clasificación de la calidad de la evidencia y la fuerza de las recomendaciones. GRADE Working Group. Atención Primaria. 2006;37(1): 5-8.
- 9.- Marzo M, Alonso P. El sistema GRADE para la toma de decisiones clínicas y la elaboración de recomendaciones y guías de práctica clínica Aten Primaria. 2007;39(9):457-60
- 10.- Agencia Calidad Sanitaria de Andalucía (AETSA): <http://www.juntadeandalucia.es/salud/servicios/aetsa/> (Acceso 17 de Julio de 2010)
- 11.- Oncoguía SEGO: Cáncer de Cuello Uterino 2008. Guías de práctica clínica en cáncer ginecológico y mamario. Publicaciones SEGO. Madrid 2008. Disponible en: <http://www.sego.es/Content/pdf/CervixOncoguia2008.pdf> (Acceso 10 de Julio de 2009)
- 12.- Dotor Gracia M, Fernández García E, Álvarez Benito M et al. Consejería de Salud. Guía de diseño y mejora continua de procesos asistenciales integrados. 2ª edición Sevilla. Junta de Andalucía, 2009.
- 13.- Consentimientos Informados Consejería de Salud Junta de Andalucía. Diponible en: http://www.juntadeandalucia.es/salud/channels/temas/temas_es/C_6_NUESTRO_COMPROMISO_POR__LA_CALIDAD/C_11_Formularios_Consentimiento_Informado/inicio_formularios_consentimiento (Acceso 17 de Julio de 2010).
- 14.- Moorhead S, Johnson M, Maas M. Clasificación de Resultados de Enfermería (NOC). 3ª Edición. Madrid: Elsevier España, 2005.
- 15.-http://www.juntadeandalucia.es/agenciadecalidadsanitaria/observatorioseguridadpaciente/gestor/sites/PortalObservatorio/es/menu/practicasSeguras/Practicas_seguras_en_Cirugia_y_Anestesia. (Acceso 17 de Julio de 2010).
- 16.- Green JA; Kirwan JM; Tierney JF; Symonds P; Fresco L; Collingwood M; Williams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 8; 358: 781-6.
- 17.- Green J; Kirwan J; Tierney J; Vale C; Symonds P; Fresco L; Williams C; Collingwood M. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005; 20; (3):CD002225.
- 18.- Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007; 25:2952-2965.
- 19.- Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S; Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 ; 25(19):2804-10.
- 20.- Stehman FB; Ali S; Keys HM; Mudderspach LI; Chafe WE; Gallup DG; Walker JL; Gersell D. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. SO Am J Obstet Gynecol. 2007; 197(5):503.e1-6.
- 21.- Verleye L, Vergote I, Reed N, Otevang PB. Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG). Ann Oncol. 2009; 20(10):1631-8.
- 22.- Trimbos JB, Franchi M, Zanaboni F, Velden J, Vergote I. 'State of the art' of radical hysterectomy; current practice in European oncology centres. Eur J Cancer. 2004; 40(3):375-8.

- 23.- Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA*. 2002; 287(16):2114-9.
- 24.- Schiffman M; Castle PE; Jeronimo J; Rodriguez AC; Wacholder S. Human papillomavirus and cervical cancer. *Lancet*. 2007 8; 370: 890-907.
- 25.- Institute for Clinical Systems Improvement . Initial Management of Abnormal Cervical Cytology (Pap Smear) and HPV Testing. Eighth Edition/October 2008. (Disponibile en [http:// www.icsi.org](http://www.icsi.org). (Acceso 27 de Julio 2009).
- 26.- American Society of Colposcopy and Cervical Pathology. Consensus guidelines. Disponible en : <http://www.asccp.org/consensus.shtml> (Acceso 29 de Septiembre de 2009)
- 27.- Management of abnormal cervical cytology and histology. ACOG Practice Bulletin N° 99. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2008; 112:1419-44.
- 28.- Sherman ME, Schiffman M, Cox JT. Effects of age and human Papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study (ALTS). *J Natl Cancer Inst* 2002; 94:102-07.
- 29.- Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. *J Low Genit Tract Dis*. 2007; 11(4):201-22.
- 30.- Duerr A, Paramsothy P, Jamieson DJ, Heilig CM, Klein RS, Cu-Uvin S, et al. Effect of HIV infection on atypical squamous cells of undetermined significance. *Clin Infect Dis* 2006; 42:855-61.
- 31.- Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. *J Acquir Immune Defic Syndr* 2001; 27:432-42.
- 32.- Massad LS, Schneider MF, Watts DH, Strickler HD, Melnick S, Palefsky J, Anastos K, Levine AM, Minkoff H. HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. *J Womens Health*. 2004 ;13(2):147-53.
- 33.- Kirby TO, Allen ME, Alvarez RD, Hoesley CJ, Huh WK. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. *J Lower Gen Tract Dis* 2004; 8:298-303.
- 34.- ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. *Am J Obstet Gynecol*. 2003 ; 188(6):1393-400.
- 35.- Castle PE, Cox JT, Jerónimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). *Obstet Gynecol*. 2008; 111(4):847-56.
- 36.- Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. *Cancer* 2006;106:1054-64.
- 37.- Dunn TS, Bajaj JE, Stamm CA, Beaty B. Management of the minimally abnormal Papanicolaou smear in pregnancy. *J Lower Gen Tract Dis* 2001; 5:13-7.

- 38.- Melnikow J, Nuovo J, Paliescheky M, et al. Detection of high-grade cervical dysplasia: impact of age and Bethesda system terminology. *Diagn Cytopathol* 1997; 17:321-25.
- 39.- Sharpless KE, Schnatz PF, Mandavilli S, et al. Dysplasia associated with atypical glandular cells on cervical cytology. *Obstet Gynecol* 2005; 105:494-500.
- 40.- Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. *Cytopathology*. 2008; 19(6):342-54.
- 41.- Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W. European guidelines for clinical management of abnormal cervical cytology, part 2. *Cytopathology*. 2009; 20(1):5-16.
- 42.- Boardman LA, Stanko C, Weitzen S, Sung CJ. Atypical squamous cells of undetermined significance human papillomavirus testing in adolescents. *Obstet Gynecol* 2005; 105:741-6.
- 43.- Moscicki AB, Shiboski S, Hill NK, Powell KJ et al. Regresión de low-grade squamous intra-epithelial lesion in young women. *Lancet* 2004; 364:1678-83.
- 44.- Puig-Tintoré LM, Corte J, Castellsagué X, Torne A et al. Prevención del cáncer de cuello uterino. *Progresos en Obstetricia y Ginecología* 2006; 49 extraordinario: 57-62
- 45.- Provencher DM, Murphy J. The Role of HPV Testing. *Journal of Obstetrics and Gynaecology Canada* 2007; 29 (8): S15-22.
- 46.- Committee on Adolescent Health Care. ACOG Committee Opinion No. 436:evaluation and management of abnormal cervical cytology and histology in adolescents. *Obstet Gynecol*. 2009; 113(6):1422-5.
- 47.- Walker P, Dexeus S, De Palo G, Barrasso R, Campion M, Girardi F, Jakob C, Roy M, from the Nomenclature Committee of the IFCCP. International Terminology of Colposcopy: An Updated Report from the IFCCP. *Obstet Gynecol* 2003;101:175-7.
- 48.- Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan Wiener NHG, Herbert A, Daniel J, Von Karsa L. European guidelines for quality assurance in cervical cancer screening. International Agency for Research Cancer. Second Edition. Office for Official Publications of the European Communities. Belgium 2008.
- 49.- Kalof A, Dadmanesh F, Longacre T, Nucci M R, Oliva E, Cooper K, College of American Pathologists. Uterine Cervix Disponible en: <http://www.cap.org/apps/docs/committees/cancer>. (Acceso 17 de Enero 2010).
- 50.- Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical displasia: histologic evaluation, treatment, and outcomes. *AmJ Obstet Gynecol* 2007; 197(2):141-6.
- 51.- Widdice LE, Moscicki AB. Updated Guidelines for Papanicolaou Tests, Colposcopy, and Human Papillomavirus Testing in Adolescents. *Journal of Adolescent Health* 2008; (43):S41-S51.
- 52.- Moscicki AB. Management of adolescent who have abnormal cytology and histology. *Obstet Gynecol Clin North Am* 2008; 35(4): 633-43.
- 53.- American Society of Anaesthesiologists. ASA standards, guidelines and statements. Illinois: ASA, 1993. Disponible en: <http://www.asahq.org/> (Acceso 13 de Enero de 2010).
- 54.- Guido R, Schiffman M, Solomon D, et al. por el ASCUS-LSIL Triage Study (ALTS) Group: Postcolposcopy management strategies for women referred with low-grade squamous

- intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: A two-year prospective study. *Am J Obstet Gynecol.* 2003; 188: 1401-1405.
- 55.- Bar-Am A, Gamzu R, Levin I, et al. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up. *Gynecol Oncol.* 2003; 91:149-153.
- 56.- Mergui JL, Levêque J What kind of follow-up after surgical treatment for high-grade cervix lesion?. *Gynecol Obstet Fertil.* 2008; 36(4):441-7.
- 57.- Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Post-treatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. *Am J Obstet Gynecol.* 2009 ; 200(4):422. e1-9.
- 58.- Prendiville W. The treatment of CIN: what are the risks? *Cytopathology.* 2009 Jun; 20(3):145-53.
- 59.- Soutter WP, Sasieni P y Panoskaltzis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. *Int. J. Cancer* 2005; 118: 2048-2055.
- 60.- Schockaert S; Poppe W; Arbyn M; Verguts T; Verguts J . Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. *Am J Obstet Gynecol.* 2008; 199(2):113-15.
- 61.- FIGO Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. Third edition. Octubre 2006.
- 62.- Edge, S.B.; Byrd, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A. *AJCC Cancer Staging Handbook* 7th ed., 2010, XIV, 730 p
- 63.- Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet.* 2009 ; 105(2):103-4.
- 64- Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. *Int J Gynaecol Obstet.* 2009 ; 105(2):107-8.
- 65.- Management of cervical cancer. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network. 2008. Disponible en: [http:// www.sign.ac.uk /pdf/sign99](http://www.sign.ac.uk/pdf/sign99). (Acceso 15 Junio 2009).
- 66.- Kesic V. Management of cervical cancer. *Eur. J. Surg. Oncol.* 2006; 32: 832-7.
- 67.- American Cancer Society. Cancer Fact and Figures 2008. Atlanta, Ga: American Cancer Society; 2008. Disponible en: [http:// www.cancer.org](http://www.cancer.org) (Acceso 15 de Junio de 2009).
- 68.- National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology. Cervical Cancer Version 1.2010. Disponible en: [http:// www.nccn.org](http://www.nccn.org) (Acceso 15 de Julio de 2010).
- 69.- PDQ database. Cervical cancer. Bethesda, Md: National Cancer Institute; 2006. Disponible en: [http:// www.cancer.gov](http://www.cancer.gov) (Acceso 15 de Junio de 2009).
- 70.- Haie-Meder C, Morice P, Castiglione M; ESMO Guidelines Working Group. Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol.* 2009 ; 20 Suppl 4:27-8.
- 71.- National Institute for Health and Clinical Excellence (NICE). Interventional procedure guidance. Laparoscopic radical hysterectomy for early stage cervical cancer. 2010. Disponible en: [http://www.nice.org.uk/ nice-media/ live/ 11044/ 48565/ 48565.pdf](http://www.nice.org.uk/nicemedia/live/11044/48565/48565.pdf) (Acceso 15 de Julio de 2010).
- 72- Panici PG, Plotti F, Zullo MA et al. Pelvic lymphadenectomy for cervical

carcinoma: laparotomy extraperitoneal, transperitoneal or laparoscopic approach? A randomized study. *Gynecol. Oncol.* 2006; 103: 859-864.

73.- Larciprete G, Casalino B, Segatore MF, Jarvis S, Catarinella V, Cirese E. Pelvis lymphadenectomy for cervical cancer: extraperitoneal versus laparoscopic approach. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2006; 126: 159-63.

74.- Zigelboim J, Ramirez PT, Gao F, Slomovitz BM, Sun C, Frumovitz M et al. Retroperitoneal lymph node resection in patients with cervical cancer. *Surgical Oncol.* 2006; 15: 79-83.

75.- Mota F, Vergote I, Trimbos JB, Amant F, Siddiqui N, Del Rio A, Verheijen R, Zola P. Classification of radical hysterectomy adopted by the Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer. *Int J Gynecol Cancer.* 2008 ; 18(5):1136-8.

76.- Landoni F; Maneo A; Cormio G; Perego P. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. *Gynecol Oncol* 2001; 80(1):3-12.

77.- Dargent D. Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer. *Am J Obstet Gynecol.* 2001; 185(2):370-4.

78.- Koliopoulos G, Sotiriadis A, Kyrgiou M, Martin-Hirsch P, Makrydimas G, Paraskeva E. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. *Gynecol Oncol* 2004; 93(2):469-73.

79.- Plante M, Renaud mc, Hoskins IA, Roy M. Vaginal radical trachelectomy: A valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies

and review of the literature. *Gynecol Oncol* 2005; 98(1):3-10.

80.- Hertel H, Kohler C, Grund D, Hillemanns P, Possover M, Michels W, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. *Gynecol Oncol* 2006; 103(2):506-11.

81.- Moore P, Benchaib M, Buenerd A, et al. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): A comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). *Gynecol Oncol* 2007; 106(1):132-141.

82.- Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. *Am J Obstet Gynecol.* 2008 ; 199(1):3-9.

83.- Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. *Am J Obstet Gynecol.* 2008 ; 199(1):10-8.

84.-Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J et al. Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3Dimage-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006; 78: 67-77.

85- Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH, Chen TH. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. *Eur J Cancer Care (Engl).* 2008 ; 17(2):174-81.

86.- Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. *J Clin Oncol.* 2004; 22(5):872-80.

87.- Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. *Int J Radiat Oncol Biol Phys.* 2006 ; 65(1):169-76.

88.- Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol.* 2004; 22(15):3113-9.

89.- Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, Kataoka M, Suzuki K, Ii N, Uno T, Takanaka T, Higuchi K, Yamazaki H, Tokumaru S, Oguchi M, Hayakawa K; Japanese Isolated Para-Aortic Lymph Node Recurrence of Uterine Cervical Carcinoma Study Group. Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. *Int J Radiat Oncol Biol Phys.* 2006; 66(5):1366-9.

90.-Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. *Int J Gynecol Cancer* 2007; 7(6):1194-204.

91.- Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group

Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2005 20;23(21):4626-33.